Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) met with German regulators on a policy roundtable to come up with adult-use pot regulations in the country.
On Tuesday, the leading cannabis producer announced it had a meeting with the German narcotic drugs commissioner at the Federal Ministry of Health Burkhard Blienert where he presented a plan for adult-use cannabis legalization and reassured a draft of the regulation will be presented in the upcoming months.
Other participants included Kristine Lütke who is a drug policy spokesperson and member of the Bundestag (FDP), finance committee representative and member of the Bundestag (SPD) Carlos Kasper and Martina Stamm-Fibich who is a member of the Bundestag (SPD) and a representative for the committee on health.
Read more: Germany takes further steps towards adult-use cannabis legalization
Read more: Germany’s new government says it will legalize cannabis
“We are honoured to have initiated this high-level exchange on one of the world’s most important cannabis endeavours,” Tilray’s chief strategy officer Denise Faltischek said in a statement.
“As a leading global cannabis company, Tilray Brands has unmatched experience partnering with governments and regulators to help develop responsible cannabis regulations that protect the health and safety of patients and consumers, as well as, supporting significant economic growth in countries in which it operates,” she added.
“We applaud the German government in leading responsible adult-use cannabis legislation in Europe and we are proud to support this effort,” Faltischek said.
Tilray Europe managing director Sascha Mielcarek said the company is a market leader in Germany and Europe and the company’s highest priority is to lead with the highest quality-control standards that are consistent and reliable for pot consumers.
“Established quality certifications such as European Good Manufacturing Practice (EU-GMP) already enable manufacturers industry-wide to provide patients and consumers with cannabis of the utmost quality and safety,” Mielcarek said.
“These standards have proven themselves in our everyday medical cannabis practice and can be considered best practices for the recreational market, as they ensure consistent quality products.”